PCSK9 and COVID-19: PCSK9 targeting has been suggested in several studies9,26–31, A recent clinical study named IMPACT-SIRIO 5 (Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19, compared the patients with severe COVID-19 treated with PCSK9 inhibitor had significantly lower rates of death or need for intubation within 30 days compared to those who received the placebo29.